Colony Group’s bluebird bio BLUE Stock Holding History

Colony Group’s Portfolio BLUE Stock Details BLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$128K	Buy	2,097 +131	+7%	+$9.2K	﹤0.01%	740
2023 Q2	$129K	Sell	1,966 -83	-4%	-$6.07K	﹤0.01%	745
2023 Q1	$130K	Sell	2,049 -1,481	-42%	-$169K	﹤0.01%	761
2022 Q4	$489K	Buy	3,530 +1,500	+74%	+$211K	0.01%	627
2022 Q3	$257K	Sell	2,030 -37	-2%	-$4.19K	﹤0.01%	685
2022 Q2	$171K	Buy	2,067 +352	+21%	+$27.3K	﹤0.01%	789
2022 Q1	$166K	Buy	1,715 +420	+32%	+$55.4K	﹤0.01%	815
2021 Q4	$259K	Sell	1,295 -1,543	-54%	-$364K	﹤0.01%	730
2021 Q3	$702K	Sell	2,838 -2,721	-49%	-$778K	0.01%	496
2021 Q2	$2.3M	Buy	+5,559	New	+$2.2M	0.05%	285

Other funds holding BLUE

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Colony Group's BLUE Position: Q3 2023 in Review

Colony Group increased its bluebird bio (BLUE) stake by 6.7% in Q3 2023, buying an estimated $9.2K and bringing the position to 2,097 shares worth $128K. The position accounts for ﹤0.01% of the portfolio, ranked #740.

Colony Group first reported a position in BLUE in Q2 2021 and has held it in 10 quarters since. The position peaked at $2.3M in Q2 2021. 168 funds tracked by Wall St. Rank hold BLUE as of Q3 2023.

Colony Group held 2,097 shares of bluebird bio worth $128K as of Q3 2023.
Colony Group bought 131 bluebird bio shares in Q3 2023, an estimated $9.2K.
bluebird bio made up ﹤0.01% of Colony Group's portfolio in Q3 2023, its #740 holding.
Colony Group first reported a position in bluebird bio in Q2 2021 and has held it in 10 quarters since.
Colony Group's bluebird bio position peaked at $2.3M in Q2 2021.
168 funds tracked by Wall St. Rank held bluebird bio as of Q3 2023.

Based on Colony Group's 13F filing for Q3 2023, filed 14 Nov 2023.